Trial · NCT03290248
Outcomes15
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 | Baseline to Day 28 | Population included subjects from Part 1 of the study and those who had received at least one dose of study medication. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Change in Total Nasal Symptom Score (TNSS) After Prophylaxis Treatment | Visit 3 (or alternative baseline at Visit 2) to Visit 4 (14 days prophylaxis treatment). Visit 2 was used as an alternate baseline to report baseline values prior to any nasal allergen challenge (NAC) to minimize any potential priming effects. | Population includes only patients from Part 2 of the study. | score on a scale*hours | MEAN |
| SECONDARY | Subjective Nasal Symptom Scores of Nasal Congestion After Prophylaxis Treatment | Visit 3 (or alternative baseline at Visit 2) to Visit 4 (14 days prophylaxis treatment). Visit 2 was used as an alternate baseline to report baseline values prior to any nasal allergen challenge (NAC) to minimize any potential priming effects. | Population includes only patients from Part 2 of the study. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Subjective Nasal Symptom Scores of Rhinorrhea After Prophylaxis Treatment | Visit 3 (or alternative baseline at Visit 2) to Visit 4 (14 days prophylaxis treatment). Visit 2 was used as an alternate baseline to report baseline values prior to any nasal allergen challenge (NAC) to minimize any potential priming effects. | Population includes only patients from Part 2 of the study. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Subjective Nasal Symptom Scores of Nasal Itching After Prophylaxis Treatment | Visit 3 (or alternative baseline at Visit 2) to Visit 4 (14 days prophylaxis treatment). Visit 2 was used as an alternate baseline to report baseline values prior to any nasal allergen challenge (NAC) to minimize any potential priming effects. | Population includes only patients from Part 2 of the study. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Subjective Nasal Symptom Scores of Sneezing After Prophylaxis Treatment | Visit 3 (or alternative baseline at Visit 2) to Visit 4 (14 days prophylaxis treatment). Visit 2 was used as an alternate baseline to report baseline values prior to any nasal allergen challenge (NAC) to minimize any potential priming effects. | Population includes only patients from Part 2 of the study. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Nasal Symptom-free Response Rate in Nasal Congestion Scores After Prophylaxis Treatment | Visit 3 (or alternative baseline at Visit 2) to Visit 4 (14 days prophylaxis treatment). Visit 2 was used as an alternate baseline to report baseline values prior to any nasal allergen challenge (NAC) to minimize any potential priming effects. | Population includes only patients from Part 2 of the study. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Nasal Symptom-free Response Rate in Rhinorrhea Scores After Prophylaxis Treatment | Visit 3 (or alternative baseline at Visit 2) to Visit 4 (14 days prophylaxis treatment). Visit 2 was used as an alternate baseline to report baseline values prior to any nasal allergen challenge (NAC) to minimize any potential priming effects. | Population includes only patients from Part 2 of the study. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Nasal Symptom-free Response Rate in Nasal Itching Scores After Prophylaxis Treatment | Visit 3 (or alternative baseline at Visit 2) to Visit 4 (14 days prophylaxis treatment). Visit 2 was used as an alternate baseline to report baseline values prior to any nasal allergen challenge (NAC) to minimize any potential priming effects. | Population includes only patients from Part 2 of the study. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Nasal Symptom-free Response Rate in Sneezing Scores After Prophylaxis Treatment | Visit 3 (or alternative baseline at Visit 2) to Visit 4 (14 days prophylaxis treatment). Visit 2 was used as an alternate baseline to report baseline values prior to any nasal allergen challenge (NAC) to minimize any potential priming effects. | Population includes only patients from Part 2 of the study. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Nasal Symptom-free Response Rate in TNSS After Prophylaxis Treatment | Visit 3 (or alternative baseline at Visit 2) to Visit 4 (14 days prophylaxis treatment). Visit 2 was used as an alternate baseline to report baseline values prior to any nasal allergen challenge (NAC) to minimize any potential priming effects. | Population includes only patients from Part 2 of the study. | Participants | COUNT_OF_PARTICIPANTS |
| OTHER_PRE_SPECIFIED | Change in Peak Nasal Inspiratory Flow (PNIF) | Visit 3 (or alternative baseline at Visit 2) to Visit 4 (14 days prophylaxis treatment). Visit 2 was used as an alternate baseline to report baseline values prior to any nasal allergen challenge (NAC) to minimize any potential priming effects. | Population includes only patients from Part 2 of the study. | L*Hr/min | MEAN |
| OTHER_PRE_SPECIFIED | Nasal Inflammation Score Using Otoscope | Visit 3 (or alternative baseline at Visit 2) to Visit 4 (14 days prophylaxis treatment). Visit 2 was used as an alternate baseline to report baseline values prior to any nasal allergen challenge (NAC) to minimize any potential priming effects. | Population includes only patients from Part 2 of the study. | Participants | COUNT_OF_PARTICIPANTS |
| OTHER_PRE_SPECIFIED | Intranasal Nitric Oxide Levels | Visit 3 (or alternative baseline at Visit 2) to Visit 4 (14 days prophylaxis treatment). Visit 2 was used as an alternate baseline to report baseline values prior to any nasal allergen challenge (NAC) to minimize any potential priming effects. | Population includes only patients from Part 2 of the study. | ppb | MEAN |
| OTHER_PRE_SPECIFIED | Change in Cytokine Concentration in Nasal Cavity and Blood | Visit 3 (or alternative baseline at Visit 2) to Visit 4 (14 days prophylaxis treatment). Visit 2 was used as an alternate baseline to report baseline values prior to any nasal allergen challenge (NAC) to minimize any potential priming effects. | Data was not collected for this exploratory endpoint. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03290248/outcomes